KRED

Wednesday, June 14, 2017

Infinity to Participate in Three Upcoming Conferences

http://www.infi.com

CAMBRIDGE, Mass., June 14, 2017 /PRNewswire/ — Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma),…

June 14, 2017 at 05:53PM

http://ift.tt/2s9SMNO

from

http://ift.tt/2s9SMNO